Dafni G Graikioti

Mrs. Dafni G Graikioti

Chemistry, University of Patras, Rio, Greece
orcid
Chemist, MSc

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
MCMacarena Funes Chabán
Macarena Funes Chabán
Martina Hrast RambaherMartina Hrast Rambaher
Martina Hrast Rambaher
Rok FrlanRok Frlan
Rok Frlan
DGDafni G Graikioti
Dafni G Graikioti
Constantinos AthanassopoulosConstantinos Athanassopoulos
Constantinos Athanassopoulos
MCMaría Cecilia Carpinella
María Cecilia Carpinella
Enzymes MurA and MurF, involved in bacterial cell wall synthesis, have been validated as targets for the discovery of novel antibiotics. A panel of plant-origin antibacterial diterpenes and synthetic analogs derived therefrom were investigated for their inhibitory properties on these enzymes from Escherichia coli and Staphylococcus aureus. Six compounds were proven to be effective for inhibiting MurA from both bacteria, with IC50 values ranging from 1.1 to 25.1 µM. To further mechanistically investigate the nature of binding and to explain the activity, these compounds were docked into the active site of MurA from E. coli. The aromatic ring of the active compounds showed a T-shaped π–π interaction with the phenyl ring of Phe328, and at least one hydrogen bond was formed between the hydroxy groups and Arg120 and/or Arg91. The results disclosed here establish new chemical scaffolds for the development of novel entities targeting MurA as potential antibiotics to combat the threat of pathogenic bacteria, particularly resistant strains.

2 February 2023 in Molecules
Verified
Journal Article
Open access
PDF file
AFAngelica Ferro
Angelica Ferro
DGDafni G Graikioti
Dafni G Graikioti
EGEmre Gezer
Emre Gezer
Constantinos AthanassopoulosConstantinos Athanassopoulos
Constantinos Athanassopoulos
MCMuriel Cuendet
Muriel Cuendet
Although proteasome inhibitors have emerged as the therapeutic backbone of multiple myeloma treatment, patients often relapse and become drug refractory. The combination between proteasome and histone deacetylase inhibitors has shown to be more efficient compared to monotherapy by enhancing the anti-myeloma activity and improving the patient’s lifetime expectancy. Hybrid molecules, combining two drugs/pharmacophores in a single molecular entity, offer improved effectiveness by modulating more than one target and circumventing differences in the pharmacokinetic and pharmacodynamic profiles, which are the main disadvantages of combination therapy. Therefore, eleven histone deacetylase-proteasome inhibitor hybrids were synthesized, combining pharmacophores of entinostat and bortezomib. Compound 3 displayed the strongest antiproliferative activity with an IC50 value of 9.5 nM in the multiple myeloma cells RPMI 8226, 157.7 nM in the same cell line resistant to bortezomib, and 13.1 nM in a 3D spheroid model containing multiple myeloma and mesenchymal stem cells. Moreover, the compound inhibited 33% of histone deacetylase activity when RPMI 8226 cells were treated for 8 h at 10 µM. It also inhibited the proteasome activity with an IC50 value of 23.6 nM.

16 December 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DGDafni G Graikioti
Dafni G Graikioti
Constantinos AthanassopoulosConstantinos Athanassopoulos
Constantinos Athanassopoulos
ASanna schito
anna schito
Silvana AlfeiSilvana Alfei
Silvana Alfei
Background: To meet the urgent need for novel antibacterial agents that are active also against worrying superbugs, natural pentacyclic triterpenoids, including totally inactive betulin (BET) and betulinic acid (BA), as well as ursolic acid (UA), active on Gram-positive bacteria, have been chemically modified, achieving compounds 1–7. Methods: Triterpenoid derivatives 1–7 and all synthetic intermediates were characterized by chemometric-assisted FTIR and NMR spectroscopy, as well as by other analytical techniques, which confirmed their structure and high purity. Minimum inhibitory concentration values (MICs) of 1–7, BET, BA and UA were determined by the broth dilution method, using a selection of Gram-positive and Gram-negative clinically isolated superbugs. Results: Performed experiments evidenced that compounds 4–7 had potent antibacterial effects against Gram-positive methicillin-resistant Staphylococcus aureus and S. epidermidis (MRSA and MRSE), as well as against vancomycin-resistant Enterococcus faecalis and E. faecium (VRE). The antibacterial effects of 4–7 were due to the insertion of a triphenyl phosphonium (TPP) group and were higher than those reported so far for other BET, BA and UA derivatives, especially considering the complex pattern of resistance of the isolates used here and their clinical source. Conclusions: For the first time, by inserting TPP, a real activity (MICs 2–16 µg/mL) was conferred to inactive BET and BA (MICs > 1024 and 256 µg/mL). Moreover, the antibacterial effects of UA were improved 16- and 32-fold against MRSE and MRSA (MICs = 2 vs. 32 and 64 μg/mL). Future Perspectives: Based on these very promising microbiologic results, new experiments are currently underway with the best-performing compounds 5 and 7 (MICs = 2 μg/mL) on an enlarged number of Gram-positive isolates, to confirm their MICs. Moreover, investigations about their possible antibiofilm activity, time-killing curves and cytotoxicity on eukaryotic cells will be carried out to define their pharmacological behavior and clinical potential.

1 January 2026 in Oncology Research
Verified
Journal Article
Open access
EPEVANGELIA PANTAZAKA
EVANGELIA PANTAZAKA
DPDimitrios Papakonstantinou
Dimitrios Papakonstantinou
ARArgyro Roumeliotou
Argyro Roumeliotou
DGDafni G Graikioti
Dafni G Graikioti
STSotirios Tsakas
Sotirios Tsakas
Galatea KallergiGalatea Kallergi
Galatea Kallergi
Objectives: Circulating tumor cells (CTCs) drive metastasis and exhibit resistance to conventional therapies, making them crucial therapeutic targets. Artesunate (AS), a derivative of artemisinin, displays anticancer activity, including inhibition of JunB proto-oncogene (JUNB) and programmed death ligand-1 (PD-L1) and upregulation of Vimentin (VIM), markers related to poor prognosis in CTCs. This study aimed to evaluate the effects of AS on adherent and non-adherent cancer cell lines (breast, lung, colon), the patient-derived colon cancer CTC-MCC-41 line, and CTCs from small-cell lung cancer (SCLC) patients. Methods: AS’s effect was evaluated using TetherChip technology. Cell viability was measured using MTT assay, while immunofluorescence staining and the VyCAP platform were applied to characterize and quantify CTCs. Results: AS significantly reduces viability in all tested cell lines in a time- and concentration-dependent manner, with non-adherent cells showing higher resistance. Notably, CTC-MCC-41 cells are the most sensitive to AS treatment. AS demonstrates stronger cytotoxicity than 5-fluorouracil (5-FU) in most cancer models. In SCLC patient samples, AS reduces total CTC counts (p < 0.001), eliminates aggressive phenotypes such as (CK+/CXCR4+/JUNB–) and (CK+/VIM+/GLU+), and increases apoptotic (M30+) CTCs (p = 0.021). AS additionally impairs structural features like microtentacles, which facilitate CTC reattachment. Conclusions: These findings underscore AS’s ability to target metastasis-competent and anoikis-resistant tumor cells, reducing their viability, invasiveness, and survival mechanisms. AS emerges as a promising candidate for anti-metastatic therapy and warrants further investigation in precision oncology.

Verified
Journal Article
Open access
PDF file
Silvana AlfeiSilvana Alfei
Silvana Alfei
Cinzia DomenicottiCinzia Domenicotti
Cinzia Domenicotti
STSara Tirendi
Sara Tirendi
ELAHEH KHALEDIZADEHELAHEH KHALEDIZADEH
ELAHEH KHALEDIZADEH
DGDafni G Graikioti
Dafni G Graikioti
Barbara MarengoBarbara Marengo
Barbara Marengo
High-risk neuroblastoma (HR-NB) remains a major clinical challenge due to the emergence of therapy resistance. In this study, the anticancer effects of seven previously synthesized betulin (BET), betulinic acid (BA) and ursolic acid (UA) derivatives (1–7) and of their natural precursors BET, BA and UA (8–10) were investigated in HTLA NB cells, selected as the experimental model by MTT assay, to find a possible solution to drugs that have lost their effect. Dynamic light scattering (DLS) analysis showed that amphiphilic compounds 1 and 4–7 form nanovesicles (240–448 nm) in water, while all compounds have high positive ζ-potential (ζ-p, +28.5–+83.1 mV), supporting favourable membrane interaction and cellular uptake. Cytotoxic experiment results and related IC50 values were expressed as the mean ± SD of four independent experiments run in triplicate. Most derivatives exhibited a cytotoxic activity higher than that of their natural precursors and outperformed etoposide; they were particularly effective against the multidrug resistant (MDR) HTLA ER cells. Among them, the ursolic acid (UA) derivative 7 emerged as the most active compound, displaying sub-micromolar to low micromolar IC50 values and markedly improving the activity of native UA. Functional studies revealed that it induces complete suppression of clonogenic growth at low micromolar concentrations in both HTLA ER and parental HTLA 230 NB cells. In addition, a concentration-dependent downregulation of Akt, p-Akt, BMI1 and PARP, was observed consistently with a marked suppression of survival pathways and loss of cellular homeostasis. Collectively, our experiments, which need further direct investigation to confirm subsequent assumption, could suggest that compound 7 could kill cancer cells via a non-apoptotic, bioenergetic collapse mechanism. All of these findings suggest compound 7 as a promising mitochondria-targeted lead candidate and support amphiphilic triterpenoid derivatives as attractive platforms for overcoming multidrug resistance in high-risk NB.

1 January 2026 in RSC Advances
Verified
Journal Article
Open access
JLJerónimo Laiolo
Jerónimo Laiolo
ATArtemis Tsirogianni
Artemis Tsirogianni
CBCecilia L. Barbieri
Cecilia L. Barbieri
MJMariana Belén Joray
Mariana Belén Joray
DGDafni G Graikioti
Dafni G Graikioti
MCMaría Cecilia Carpinella
María Cecilia Carpinella
Screening novel artemisinin derivatives identified A16 and A20 as potent Rho123 efflux inhibitors (MEC: 49 nM), enhancing doxorubicin (Dox) cytotoxicity in K562/Dox cells at 50 and 5 nM, respectively.